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1. Introduction  
Giant cell arteritis (GCA), also called Horton, temporal, or granulomatous arteritis,  is a 
primary vasculitis that affects extracranial medium (especially branches of the external 
carotid artery) and large-sized arteries (aorta and its major branches) (Levine&Hellmann, 
2002). The diagnosis of GCA requires age more than 50 years at disease onset, new headache 
in the temporal area, temporal artery tenderness, and/or reduced pulse, jaw claudication, 
systemic symptoms, erythrocyte sedimentation rate (ESR) exceeding 50 mm/ hr, and typical 
histologic findings (granulomatous involvement) in temporal artery biopsy (Hunder et al., 
1990). Approximately 40-50% of these patients have ophthalmologic complications, 
consisting of visual loss secondary to arteritic anterior ischemic optic neuropathy (AION), or 
central retinal artery occlusion (CRAO), homonymous hemianopsia or cortical blindness 
(unilateral or bilateral occipital infarction) (Gonzales-Gay, 2005).  
2. Epidemiology 
Over the last 25–30 years, GCA has been found to be the most common type of vasculitis in 
Europe and North America. Incidence of GCA is higher in white individuals than those of 
other ethnicities. The highest incidence rates are reported in Scandinavian countries and 
North American populations of the same descent. In these regions, the annual incidence 
rates are generally higher than 17/100,000 people per population age 50 years (Salvarani et 
al., 1995). The incidence of GCA is lower than 12/100,000 people per population age 50 
years in Southern European and Mediterranean countries.  
The incidence increases with age  and peaks in the 70–79 years age group: 100,000 people 
per population age 50 years. 
In Northern European countries, women are affected more frequently  than men (3:1 to 5:1). 
A lower ratio of women to men was observed in Southern Europe and Israel (Salvarani et 
al., 1991). 
As the population throughout the world continues to age, an increased prevalence of 
disease should be expected.  
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Higher physician awareness was proposed as being responsible for the progressive increase 
of GCA reported in different parts of the world (Gonzales-Gay et al., 2009). 
3. Etiology  
3.1 Implication of genetic factors 
Familial aggregation of GCA has been observed. Genetic predisposition has been reported 
with an association to the human leukocyte antigen (HLA)-DRB1 molecule, and tumor 
necrosis factor microsatellite polymorphisms. Moreover, many other studies have shown 
the implication of genetic variants in key components of immune and inflammatory 
pathways in GCA susceptibility, because GCA is a polygenic disease. An increased risk of 
having visual ischemic complications in biopsy-proven GCA patients was found to be 
associated with the carriage of HLA–DRB1*04 alleles. Moreover, a functional variant of the 
vascular endothelial growth factor gene was associated with severe ischemic complications 
in patients with GCA (Gonzales-Gay, 2001). 
3.2 Influence of infectious agents 
 It has been proposed that infectious agents are a possible influence in the pathogenesis of 
GCA. Several infectious agents have been investigated as possible triggers in a susceptible 
host, with inconclusive results. Fluctuations of the incidence of GCA  in different regions of 
Denmark, supporting an association with Mycoplasma pneumoniae, parvovirus B19, and 
Chlamydia pneumoniae epidemics, were found. An association  of parvovirus B19 with GCA 
was also suggested by Gabriel et al., 1999. French investigators found an association of GCA 
with human parainfluenza virus type 1 (Gabriel et al., 1999). 
Four different recent studies did not confirm any association between the presence of 
parvovirus B19, C pneumoniae, or human herpesvirus DNA in TAB specimens and the 
histologic evidence of biopsy-proven GCA (Rodriguez-Pla, 2004).  
However, the presence of peaks in the incidence and a cyclic pattern observed in other 
studies suggests that infectious agents may play a role in the pathogenesis of both diseases. 
They could be the triggers for the development of these conditions in genetically 
predisposed individuals (Ghanchi, 1996). 
3.3 Influence of traditional cardiovascular risk factors 
(Duhaut et al, 1999), in a prospective multicenter case–control study on 207 biopsy-proven 
GCA patients, described a strong association between smoking and previous atheromatous 
disease in women and GCA. The presence of atherosclerosis risk factors at the time of 
diagnosis of the disease may influence the development of severe ischemic complications in 
patients with this vasculitis. 
4. Pathogenesis  
GCA is an autoimmune vasculitis. It involves predominantly medium-sized  arteries, 
especially the superficial temporal, ophthalmic, posterior ciliary, and other peripheral 
arteries. The typically predominant extracranial vascular involvement is explained by the 
affinity of inflammation to the elastic fibers. As intracranial arteries have less elastic fibers in 
the media, they are seldomly involved. The severity and extent of the involvement are 
associated with the quantity of elastic tissue in the media of the artery. 
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Two different types of inflammatory reactions are found in the temporal arteries in patients 
with GCA. One is related to foreign-body giant-cell reaction, directed at small calcifications 
of the internal elastic membrana. The foreign-body type of inflamation is focal, affecting 
only part of the arterial circumference. The other type of lesion is characterized by diffuse 
inflammation in which mononuclear inflammatory cells invade the layers of the arterial wall 
in the whole circumference of the vessel. (Weyand et al., 1997). 
GCA is an antigen-driven disease with local T cell and macrophage activation in the vessel 
wall, and with an important role of proinflammatory cytokines. Inflammation of the arterial 
wall and vessel occlusion through fast and concentric intimal hyperplasia leads to the severe 
ischemic complications observed in patients with GCA. Dendritic cells localized at the 
adventitia–media border of normal medium-sized arteries produce chemokines and recruit 
and locally activate T cells. Moreover, dendritic cells express a singular surface receptor 
profile, including a series of Toll-like receptors (TLRs). Ligands of TLR-4 promote activation 
and differentiation of adventitial dendritic cells into chemokine-producing effector cells 
with high-level expression of both CD83 and CD86, and mediate T cell recruitment through 
the release of interleukin-18 (IL-18). Activated T cells experience clonal expansion and are 
stimulated to produce interferon-gamma (IFN-gamma). This leads to the differentiation and 
migration of macrophages and the formation of giant cells. In the adventitia, macrophages 
produce proinflammatory cytokines such as IL-1 and IL-6, whereas in the media and intima 
they contribute to arterial injury by producing metalloproteinases and nitric oxide.  
This destructive mechanism of the arterial wall is associated with a repair mechanism that 
includes the secretion of growth and angiogenic factors (platelet-derived growth factor and 
vascular endothelial growth factor) through the infiltration of mononuclear cells and 
multinucleated giant cells. These changes ultimately lead to the degradation of the internal 
elastic lamina and to occlusive luminal hyperplasia. In addition to IL-1 and IL-6, IFN-
gamma specifically seems to play a pivotal role in the pathogenesis and in the clinical 
expression of GCA. In this regard, IFN- gamma  is expressed in nearly 70% of the temporal 
artery biopsy (TAB) samples from patients with GCA. High transcription of IFN-gamma  
messenger RNA (mRNA) was associated with the formation of giant cells and with the 
evidence of cranial ischemic symptoms in GCA patients. The absence of IFN- gamma 
expression in TAB samples from patients with isolated PMR suggests that its production 
may be crucial to the development of GCA. TAB specimens from GCA patients with ocular 
ischemia expressed high amounts of IFN-gammamRNA, whereas those from GCA patients 
with fever had less IFN-gamma mRNA. Therefore, clinical correlates suggest a role of IFN- 
gamma  in the process of lumenal obstruction. By regulating giant cell formation, IFN- 
gamma  could indirectly control intimal hyperplasia. IFN-gamma may dictate the functional 
properties of other cell populations in the vascular infiltrates and, by means of this 
mechanism, guide the response-to-injury reaction of the artery (Weyand et al., 1997). 
5. Diagnosis 
A definitive diagnosis is made following the criteria of the American College of 
Rheumatology which include: age, temporal headache, swollen temporal arteries, jaw 
claudication, eye involvement, the temporal artery biopsy, and its histologic evaluation. The 
disease affects elderly patients, with a mean age of 70 years.  
Diagnostic criteria of temporal arteritis 
Three of the five diagnostic criteria for GCA have to be met (Hunder et al., 1990): 
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1. Age 50 years or more. 
2. New developed headache. 
3. Tenderness of the superficial temporal artery. 
4. Elevated sedimentation rate (ESR), at least 50 mm/h. 
5. Giant cell arteritis in a biopsy specimen from the temporal artery. 
Large vessel giant cell arteritis is a subgroup of GCA (temporal arteritis) described in at least 
17% of cases. In these patients, inflammation occurs also at the level of the aorta and its 
branches (especially of the subclavian, the axillary arteries, etc), although symptoms of 
aortic involvement (aortic aneurysm rupture) may appear years after the initial diagnosis of 
this vasculitis (Martinez-Valle, 2010). 
Interestingly, in some cases, the common carotid arteries (CCA) and the internal carotid 
arteries (ICA) are  also involved. 
5.1 Clinical features 
The typical neurological symptoms and classic clinical features of GCA are presented by new 
moderate bitemporal headache, especially common at night, jaw claudication, scalp 
tenderness (which is first noticed when combing the hair), or abnormal superficial temporal 
arteries  (tender, nodular, swollen, and thickened arteries) on palpation (Gonzales-Gay et al., 
2005). (fig.1) 
 
 
Fig. 1. Patient MM. Dilated and nodular left superficial temporal artery.  
Initially, temporal pulsation is present, although the thickened arteries cann’t be flattened 
against the skull. The best location to feel for pulsation is directly in front of the upper pole 
of the pinna of the ear. Later, the temporal arteries present a decreased pulsatility. Lack of 
pulsation is very suggestive of GCA because it is most unusual for the superficial temporal 
arteries to be non-pulsatile in normal elderly individuals. The jaw claudication is the result 
of ischemia of the masseter muscles, which causes pain on speaking and chewing.  
A recent study aiming to establish the best set of clinical features that may predict a positive 
TAB in a community hospital disclosed that headache, jaw claudication, and abnormal 
temporal artery on palpation were the best positive predictors of positive TAB in patients on 
whom a biopsy was performed to diagnose GCA. These authors established clinical 
differences between biopsy proven GCA and biopsy-negative GCA patients. Moreover, they 
observed a non–significantly increased frequency of abnormal palpation of the temporal 
artery on physical examination in biopsy-proven GCA patients (73.3%) compared with 
biopsy-negative GCA patients (54.2%). 
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Less common neurologic complications (approximately 4% of patients) include transient 
ischemic attacks, or stroke, more frequently in the posterior circulation, than in the carotid 
territory, manifested by homonymous hemianopsia or cortical blindness (unilateral or 
bilateral occipital infarction), and audiovestibular dysfunction. They occur more commonly 
at the time of GCA diagnosis or within the first 4 weeks after the onset of corticosteroid 
therapy. Almost all patients with GCA-associated strokes have a significant acute phase 
response with elevated ESR and C-reactive protein (CRP). The mortality has been reported 
to be as high as 75%. The impact of cardiovascular risk factors on the occurrence of cerebral 
ischemic events has been evaluated in the Reggio Emilia region of Italy in patients with 
biopsy-proven TA. Both a history of hypertension or ischemic heart disease were associated 
with a higher risk of stroke (Berger et al., 2009). 
Systemic symptoms includ fever, fatigue, malaise, weight loss, and/or polymyalgia 
rheumatica. Polymyalgia rheumatica (PMR) is a disease characterized  by severe bilateral 
pain and aching involving the neck, shoulder, and pelvic girdles associated with morning 
stiffness. PMR is more common than GCA, and it may present as an isolated entity, or may 
be the presenting feature in patients who later develop typical cranial manifestations of 
GCA (Salvarani et al., 2008). Population-based studies have shown the presence of “silent” 
biopsy-proven GCA in 9–21% of the patients presenting with PMR features. Also, PMR 
manifestations are observed in up to 40–50% of patients with biopsy-proven GCA. The 
nephritic syndrome has been reported in patients with GCA in the setting of focal segmental 
glomerulonephritis, membranous glomerulonephritis, amyloidosis, and necrotizing  
glomerulonephritis. 
Ocular ischemic complications are  the major source of chronic disability among GCA patients. 
In some cases, the development of blindness may be preceded by episodes of amaurosis 
fugax. They are generally early manifestations due to the vasculitic involvement of 
retrobulbar (orbital) vessels deriving from the ophthalmic artery (OA). In unselected 
patients with biopsy-proven GCA, visual ischemic complications occur in 25% and 
irreversible visual loss occurs in 10–15% of the patients. There is a significantly increased 
frequency of severe visual ischemic complications (transient or permanent visual loss) in the 
group of biopsy-proven GCA patients compared with GCA patients with a negative TAB. 
These interesting observations are in agreement with two previous population-based 
studies that disclosed that biopsy-negative patients have less frequency of severe ischemic 
complications than those with biopsy-proven GCA. Ocular ischemic complications are 
generally due to arteritic anterior ischemic optic neuropathy (AAION). More rarely, visual 
loss is caused by central retinal artery occlusion (CRAO), or ischemic retrobulbar neuritis 
(Gonzales-Gay et al., 2000). 
Arteritic anterior ischemic optic neuropathy (AAION) results from short posterior ciliary arteries 
(SPCA) vasculitis and the consecutive optic nerve head infarction. Human autopsy studies 
of acute arteritic AION demonstrate optic disc edema with ischemic necrosis of the 
prelaminar, laminar, and retrolaminar portions of the optic nerve and infiltration of the 
SPCA by chronic inflammatory cells. In some cases segments of these vessels have been 
occluded by inflammatory thickening and thrombus (Arnold, 2004). 
Patients  with an unilateral AAION present the following key features:  
a. abrupt, painless, severe loss of vision of the affected eye. 
b. anterior segment examination of both eyes is normal. 
c. the ophthalmoscopy of the affected eye reveales diffuse pale optic disc edema, but 
within 1-2 months, the swelling gradualy resolves and the entire optic disc will become 
atrophic. (fig.2) 
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Fig. 2. Pacient TL-Fundus view of the left eye. Arteritic AION. The optic disc demonstrates 
pale, diffuse edema. 
Typically, in AAION the  severe visual loss is preceeded by transient visual loss similar to 
that of carotid artery disease. This symptom is unusual in the nonarteritic form of AION. 
The ophthalmoscopy indicates that pallor is associated with the edema of the optic disc 
more frequently in the arteritic than in the non arteritic form of AION. Although 
simultaneous bilateral involvement is rare in the arteritic form of AION, about 65% of 
untreated patients become blind in both eyes within a few weeks. The optic disc of the 
fellow eye is of normal diameter, with a normal physiological cup (absence of „disk at risk”, 
with postulated structural crowding of the axons at the level of the cribriform plate, 
associating mild disc elevation, and disc margin blurring without overt edema). 
Central Retinal Artery Occlusion (CRAO) is the result of an abrupt diminuation of blood flow 
in CRA, severe enough to cause ischemia of the inner retina. Due to the fact that there are no 
functional anastomoses between choroidal (posterior ciliary arteries) and retinal circulation 
(CRA), CRAO determines severe and permanent loss of vision. Therefore, it is very 
important to identify the cause of CRAO, in order to protect the contralateral eye. 
Frequently, the site of the blockage is within the optic nerve substance and for this reason, it 
is generally not visible on the ophthalmoscopy (Ahuja et al., 1999). 
Patients with an unilateral CRAO present the following key features:  
a. abrupt, painless, severe loss of vision of the affected eye. 
b. anterior segment examination is  normal in both eyes. 
c. the fundus of the affected eye presents: (fig 3) 
- ischemic whitening of the retina. 
- cherry-red spot in the center of the retina. 
- the site of obstruction of CRA is not visible on ophthalmoscopy (no embolus is found).  
 
 
Fig. 3. Patient MM-Fundus view of the left eye. CRAO. A prominent cherry-red spot with 
cilio-retinal artery sparing in the papillomacular bundle. 
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In only 20-25% of cases are emboli visible in the CRA or one of its branches, suggesting that 
an embolic cause is not frequent in CRAO (embolic material from either the heart, the 
ascending aorta or the ipsilateral ICA). It is currently believed that the majority of CRAO’s 
are caused by thrombus formation due to systemic diseases: haematological disorders, and 
last but not least, systemic vasculitis (including GCA). For this reason, all patients with 
CRAO should undergo a systemic evaluation (Duker, 2004). 
In CRAO the retina appears white as a result of cloudy swelling. The „cherry-red spot” 
appearence in the center of the retina is due to the relatively intact choroidal circulation, in 
contrast to the ischemic retina. (Duker, 2004). 
5.2 Laboratory findings 
Laboratory findings reveal a raised Erythrocyte sedimentation rate (ESR) and increased 
values of C-reactive protein (CRP). ESR is often very high in GCA, with levels more than 60 
mm/hr. In interpreting the ESR it should be emphasized that the levels of 40 mm/hr may be 
normal in the elderly and cases of biopsy- proven GCA have been reported in patients with 
ESR levels lower than 30 mm/hr. Approximately 20% of patients with GCA have a normal 
ESR. CRP is invariably raised in GCA and may be helpful when the ESR is equivocal 
(Lopez-Diaz, 2008). This acute phase response is induced by pro-inflammatory cytokines, 
mainly interleukins (IL) 1, 6 and tumor necrosis factor (TNF) alpha. These are produced by 
activated macrophages in the vessel wall. The target antigen of the CD4+ T cell immune 
response in GCA is probably located in the internal elastic layer of the vessel wall which 
explains that arteries of the anterior intracerebral circulation are infrequently affected 
because these lack an internal elastic layer (Weyand et al., 2003). 
Several imaging modalities may be useful to make a diagnosis of GCA. In this regard, Pipitone et al., 
2008performed an elegant review of the role of imaging studies in the diagnosis and follow-up of large 
vessel vasculitis (Pipitone et. al., 2008). 
5.3 Extracranial Duplex sonography 
Ultrasonography (US) of the temporal artery has raised great interest in the diagnosis of 
GCA. Extracranial Duplex sonography investigates almost completely the whole length of 
the common superficial temporal arteries, including the frontal and parietal branches, and 
founds that inflammation is segmental (discontinous arterial involvement). The common 
superficial temporal artery derives from the external carotid artery. It divides into the 
frontal and parietal ramus in front of the ear. The distal common superficial temporal artery 
and the rami are localized between the two layers of the temporal fascia, which is like a 
bright band at ultrasound examination (Schmidt, 2006). 
Technical requirements 
High-resolution color Doppler US can show the vessel wall and the lumen of the temporal 
arteries. One should use linear probes with a minimum gray scale frequency of 8 Mhz. Color 
frequency should be about 10 Mhz (Schmidt, 2006). 
Machine adjustments 
The pulse repetition frequency (PRF) should be about 2.5khz as maximum systolic velocities 
are rather high (20-100 cm/s). Steering of the color box and the Doppler beam should be 
maximal as the rami are paralel to the probe. It is important that the color covers the artery 
lumen exactly (Schmidt, 2006). 
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Sonographer training 
The sonographer should perform at least 50 Duplex ultrasound of the temporal arteries of 
subjects without GCA to be sure about the appearance of normal temporal arteries before 
starting to evaluate patients with GCA (Schmidt, 2006). 
Sequence of the Ultrasound examination 
The investigation should start at the common superficial temporal artery using a 
longitudinal scan. The probe should then be moved along the course of the temporal artery 
to the parietal ramus. On the way back one should deliniate the temporal artery in 
transverse scans. Using the transverse scan, one can find the frontal ramus, which should 
then be delineated in both scans (longitudinal and transverse). If the color signals indicates 
localized aliasing and diastolic flow, one should use the pw-Doppler mode to confirm the 
presence of stenoses (Schmidt, 2006). 
Schmidt et al., 1997 demonstrated that the most specific (almost 100% specificity) and 
sensitive (73% sensitivity) sign for GCA was a concentric hypoechogenic mural thickening, 
dubbed halo, which the authors interpreted as vessel wall edema. Other positive findings 
for GCA are the presence of occlusion and stenosis (Schmidt et al., 1997). 
In conclusion, three findings are important for the ultrasound diagnosis of temporal 
arteritis: 
a. „dark halo” sign – a typically hypoechoic, circumferential wall thickening around the 
lumen of an inflamed temporal artery - which represents vessel wall edema and a 
characteristic finding in temporal arteritis (TA)/GCA (Arida et al., 2010). 
b. stenoses are documented by blood-flow velocities, which are more than twice the rate 
recorded in the area of stenosis compared with the area before the stenosis, with wave 
forms demonstrating turbulence and reduced velocities behind the area of stenosis. 
(fig.4.A,B). 
 
 
Fig. 4. Patient TL-Spectral analysis CW- 8Mhz -Extracranial Doppler ultrasound of the right 
temporal artery.  
a. Peak flow velocity is 69 cm/s in the area of stenosis, and  
b. 30.3 cm/s before the stenosis. 
c. acute occlusions, in which the ultrasound image is similar to that of acute embolism in 
other vessels, showing hypoechoic material in the former artery lumen with absence of 
color signals (Schmidt et al., 1997). 
Similar ultrasound patterns can be found in other arteries: the facial, the internal maxilary, 
the lingual, the distal subclavian, and axilary arteries. (fig.5A,B.) 
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Fig. 5. Patient TL-Spectral analysis CW- 8Mhz -Extracranial Doppler ultrasound of the left 
lingual artery.  
a. Peak flow velocity is 61.9 cm/s in the area of stenosis, and  
b. 20.3 cm/s before the stenosis.  
Interestingly in some cases the common carotid and the internal carotid arteries (the CCA 
and the ICA) are also involved (large-vessel giant cell arteritis).(fig.6, fig.7).  
 
 
Fig. 6. Patient MM-B mode insonation in large vessel giant cell arteritis. Transverse view of 
the left CCA. Hypoechoic wall swelling with CCA occlusion.  
 
 
Fig. 7. Patient TL-Color Doppler ultrasound in large vessel giant cell arteritis. Longitudinal 
view of the right CCA with hypoechoic wall swelling. 
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Ultrasound investigation has to be performed before corticosteroid treatement, or within the 
first 7 days of treatment, because with corticosteroid therapy the ,,halo” revealed by 
temporal arteries ultrasound disappeares within 2-3 weeks. The wall swelling, stenoses, or 
occlusions of the larger arteries (CCA, ICA) remaines for months, despite  the corticosteroid 
therapy. Nevertheless, diagnostic assessment should not delay the start of therapy. 
Ultrasound may also detect inflamed temporal arteries in patients with clinically normal 
temporal arteries. Some patients with the clinical image of polymyalgia rheumatica, but 
with occult temporal arteritis may be diagnosed by ultrasonography. 
Arida et al., 2010 looked for studies that examined the sensitivity and specificity of the 
,,halo” sign demonstrated by temporal artery US for GCA diagnosis versus the American 
College of Rheumatology (ACR) 1990 criteria for the classification of this vasculitis (used as 
a reference standard). Only 8 studies involving 575 patients, 204 of whom received the final 
diagnosis of GCA, fulfilled the technical quality criteria for US. This metaanalysis disclosed 
a sensitivity of 68% and a specificity of 91% for the unilateral ,,halo” sign, as well as 43% and 
100%, respectively, for the bilateral ,,halo” sign in temporal artery US for GCA diagnosis 
when the 1990 ACR criteria are used as the reference standard. The authors confirmed that 
the halo sign in US is useful in diagnosing GCA (Arida et al., 2010). 
Schmidt, 2006 compared the results of temporal artery US examinations with the occurrence of 
visual ischemic complications in patients with GCA. These US results were compared with the 
occurrence of AAION, CRAO, branch retinal artery occlusion, diplopia, or amaurosis fugax in 
222 consecutive patients with newly diagnosed, active GCA. However, findings of temporal 
artery US did not correlate with eye complications (Schmidt, 2006). 
5.4 Color Doppler Imaging (CDI) of retrobulbar vessels 
We used a sonographer with 8-15 MHz linear probe for detecting (by Color Doppler 
sonography), and measuring (by spectral analysis pulsed Doppler sonography) the blood 
flow in the orbital vessels: the ophthalmic artery-OA; the central retinal artery-CRA and 
vein-CRV, posterior ciliary arteries-PCA, and the superior ophthalmic vein-SOV (Tranquart 
et al., 1997). 
The patients with an unilateral arteritic AAION present at the Spectral Doppler analysis of the 
retrobulbar vessels the following aspects:  
a. an increased resistance index (RI) in the posterior ciliary arteries (PCA) (the RI is higher 
on the affected side, than it is on the unaffected side); with severe diminished blood 
flow velocities (especially end-diastolic velocities) in the PCA. (fig.8.A, B,C,D) 
 
 
Fig. 8. A,B,C,D. Pacient TL-Spectral Doppler analysis of PCA. 
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b. less abnormalities are observed in the central retinal arteries (CRA) (fig.9.A,B) and in 
the ophthalmic arteries (OA). (fig.10.A,B)  
 
 
Fig. 9. A,B.Pacient TL-Spectral Doppler analysis of CRA.  
In conclusion, the Spectral Doppler Analysis of the orbital vessels in arteritic AION  reveales 
low blood velocities, especially end-diastolic velocities, and high RI in all retrobulbar 
vessels, in both orbits (with severe diminished blood flow velocities in the PCA, especially 
on the affected side). In nonarteritic AION blood velocities and RI in PCA are relatively 
preserved (Jianu D.&Jianu S., 2010). 
 
 
Fig. 10. A,B.Pacient TL-Spectral Doppler analysis of OA. 
Fluorescein angiogram and CDI of retrobulbar vessels data support the histopatological 
evidence of involvement of the entire trunck of the SPCA in the arteritic AION (impaired 
optic disc and choroidal perfusion in the patients  with arteritic AION). In contrast, in the 
nonarteritic AION, the impaired flow to the optic nerve head is distal to the SPCA 
themselves, possibly at the level of the paraoptic branches (only 1/3 of the flow of the 
SPCA) (Collignon-Robe et al., 2004). These branches supply the optic nerve head directly 
(impaired optic disc  perfusion, with relatively conservation of the choroidal perfusion). 
(fig.11) 
 
 
Fig. 11. Arterial vascularisation of the optic nerve. 
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Extremely delayed or absent filling of the choroid has been depicted as a  fluorescein 
angiogram characteristic of arteritic AION and has been suggested as one useful factor by 
which arteritic AION can be differentiated from nonarteritic AION. 
The patients with an unilateral CRAO present at the Spectral Doppler analysis of the 
retrobulbar vessels the following aspects (Connolly, 2000): 
a. an increased resistance index (RI) in the central retinal arteries- CRA (the RI is higher on 
the affected side, than it is on the unaffected side); with severe diminished blood flow 
velocities (especially end-diastolic velocities) in the CRA. (fig.12. A, B) 
 
 
Fig. 12. A,B.Pacient MM-Spectral Doppler analysis of CRA. 
b. less abnormalities are observed in the posterior ciliary arteries (PCA), (fig.13.A,B) and 
in the ophthalmic arteries (OA). (fig.14.A,B) 
 
 
Fig. 13. A,B.Pacient MM-Spectral Doppler analysis of PCA. 
 
 
Fig. 14. A,B.Pacient MM-Spectral Doppler analysis of OA. 
5.5 Others imaging techniques  
Inflammation of the aorta and its branches may occur in a subset of GCA patients, although 
symptoms of aortic involvement may appear years after the initial diagnosis of this 
vasculitis (large giant cell arteritis). Therefore, as emphasized by Martinez-Valle et al., 2010 a 
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systematic evaluation of patients with imaging techniques such as magnetic resonance 
angiography (MRA), computed tomographic angiography (CTA), or positron emission 
tomography (PET) may reveal that the clinical impact of extracranial involvement by GCA is 
more relevant than previously thought (Martinez-Valle et al., 2010). 
Contrast-enhanced, high-resolution MR imaging allows noninvasive assessment of the mural 
inflammation. In this regard, Bley et al., 2008 compared the results of high-resolution MRI 
and color coded duplex US in 59 patients with suspected GCA with the final clinical 
diagnosis based on the ACR classification criteria for GCA (Bley et al., 2008). Thirty-six of 
the 59 patients (61%) were ultimately diagnosed as having GCA. Sensitivity of high 
resolution MRI and color-coded duplex US was 69% and 67%, respectively, while specificity 
was 91% in both. Temporal artery biopsy findings were positive in 24 of the 41 biopsied 
patients (59%). Sensitivity of high-resolution MRI and color-coded duplex US compared 
with temporal artery biopsy was 83% and 79%, respectively, and specificity was 71% and 
59%, respectively. Therefore, differences between high-resolution MRI and color-coded 
duplex US were not significant. According to these observations, the diagnostic power of 
high-resolution MRI and color-coded duplex US in detecting GCA was comparable. These 
authors suggest that both noninvasive techniques may be useful in the assessment of 
patients with suspected GCA. 
However, these results are in contrast to those of another study performed in patients with 
suspected GCA. Ghinoi et al., 2008 performed an interesting study to determine the 
usefulness of 1 T MRI of the temporal arteries and to compare 1 T MRI with duplex US and 
physical examination of temporal arteries in the diagnosis of GCA in a series of 20 patients 
with suspected GCA (Ghinoi et al., 2008). Mural contrast enhancement of the temporal 
arteries on MRI had a sensitivity of 33.3% and a specificity of 87.5% for the diagnosis of 
biopsy-proven GCA. Compared with the diagnosis of GCA by the ACR  classification 
criteria, 1 T MRI of the temporal arteries had a sensitivity and specificity of 27.2% and 88.9%, 
respectively. Temporal artery abnormalities on physical examination and the presence of a 
hypoechoic halo on US had a higher sensitivity (66.7% and 77.7%, respectively) and a higher 
specificity. According to these observations, 1 T MRI does not seem useful in the diagnosis 
of GCA due to its low sensitivity. 
Computed tomodensitometric scan allows analysis of the arterial wall and endoluminal part of 
the aorta and its branches. (fig.15) 
 
 
Fig. 15. Patient MM with large giant cell arteritis-CT-Angiography. Occlusion of the left CCA, 
ECA, and ICA. 
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Because aortitis is a complication of GCA, Agard et al., 2008 conducted a study in a series of 
22 patients and 22 controls using computed tomodensitometric scan to assess the presence 
of aortic abnormalities in patients with recent onset GCA. Thickening of the aortic wall was 
more frequent among patients with GCA than controls (Agard et al., 2008). 
18 Fluorodeoxyglucose (FDG)-PET may be useful to detect large vessel arteritis in the setting 
of GCA, which can involve the larger thoracic, abdominal, and peripheral arteries. It may be 
particularly useful in the diagnosis of GCA patients with atypical presentations such as 
fever of unknown origin or those presenting with asthenia, anorexia, and weight loss 
without cranial ischemic manifestations. Also, as emphasized by Pipitone et al., 2008 
previous reports showed that PET may be more sensitive than MRI in detecting vessel 
inflammation in the early stage of large giant cell arteritis (Pipitone et al., 2008). However, 
PET cannot detect inflammation in the temporal arteries; therefore, it is not adequate for the 
diagnosis of cranial GCA and cannot replace temporal artery biopsy. Moreover, relapses of 
GCA cannot be predicted by results of previous PET (Henes et al., 2008). 
In conclusion, PET/CT seems useful in the diagnosis and re-evaluation of large vessel 
vasculitis. It allows the evaluation of disease activity and vessel morphology as well as the 
localization of the inflammatory process in the same session. 
5.6 Temporal Artery Biopsy (TAB) and the histopathologic picture 
A temporal artery biopsy (TAB) is the gold standard test for the diagnosis of GCA (Duhaut, 
Pinede, 1999). European League Against Rheumatism recommendations emphasize that 
TAB should be performed whenever a diagnosis of GCA is suspected. Because 
corticosteroid therapy is required in most cases for more than 1 year in GCA, the pathologic 
confirmation of this vasculitis is advisable. However, GCA affects vessels focally and 
segmentally, yielding areas of inflammatory vasculitic lesions juxtaposed with areas of 
normal artery. Histologic signs of inflammation may be missed in TABs performed in 
arteritis-free segments (Foroozan, 2003). Because of segmental (discontinous) involvement of 
temporal arteries, a biopsy result may be negative in 9-44% of patients with clinical positive 
signs of temporal arteritis; for this reason the temporal arteries biopsy has to be  guided by 
Doppler Ultrasonography and typical clinical features (tender, swollen portions of temporal 
arteries). Prior treatment with steroids for more than 7 days may be associated with loss of 
the histological features of active arteritis. As a consequence, the ultrasound investigations 
and temporal arteries biopsy has to be  performed before corticosteroid treatment. 
Interestingly, 2 population-based studies have shown that patients with negative biopsy 
samples have less frequency of severe ischemic complications than those with biopsy-
proven GCA (Breuer, 2009). 
Taylor-Gjevre et al., 2005 noted that a threshold length of 1.0 cm of postformalin fixed 
arterial segment was associated with an increased diagnostic yield of GCA (Taylor-Gjevre et 
al., 2005). They recommended collecting a minimum TAB length of 1.5 cm to allow for tissue 
shrinkage during fixation that was estimated to be about 10%. More recently, Mahr et al., 
2006  reported that a postformalin fixed TAB length of at least 0.5 cm could be sufficient to 
make a histologic diagnosis of GCA (Mahr et al., 2006). TAB is generally performed on the 
most symptomatic side. Breuer et al., 2009 performed a study to establish the relationship 
between TAB length and the diagnostic sensitivity for GCA (Breuer et al., 2009). In this 
study, the TAB in the subgroup of biopsy-positive GCA patients was significantly longer 
than in biopsy-negative GCA cases. The rate of positive biopsies was only 19% with TAB 
length of 5 mm or less but increased to 71–79% with TAB lengths of 6–20 mm, and to 89% 
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when TAB length was longer than 20 mm. Only 3% of positive biopsies were 5 mm or 
shorter. These authors concluded that TABs with postfixation length shorter than 5 mm 
yield an increased biopsy negative rate. As a result, the authors supported the claim that a 
TAB length longer than 5 mm is required for accurate diagnosis of GCA. 
In the presence of unilateral ocular involvement, we took a biopsy from the ipsilateral side 
representing 2.5 cm of the tender, swollen segments of the affected artery („skip lesions”). 
Serial sections were examined, as there could be variations in the extent of involvement 
along the length of the artery (Gonzales-Gay et  al., 2001). 
However, due to the segmental inflammatory involvement of the temporal artery, a 
contralateral biopsy may be required in patients with high clinical suspicion of GCA. Breuer 
et al., 2009 found that performing bilateral TABs increases the diagnostic sensitivity of the 
procedure by up to 12.7% compared with unilateral biopsies (Breuer et al., 2009). 
The definitive diagnosis of GCA requires the pathologic demonstration of a vasculitis with 
mononucleated cell infiltrates of all mural layers and occurrence of giant cells on a temporal 
artery biopsy. The degree of intimal hyperplasia on histology findings is associated with 
neuroophthalmic complications (Makkuni et al., 2008); the presence of giant cells in 
particular is associated with permanent visual loss (Chatelain et al., 2009). 
 
 
Fig. 16. Typical temporal arteritis Patient TL. Higher magnification showing the typical 
giant cell granulomatous inflammation. 
Patient TL. Higher magnification showing the typical giant cell granulomatous 
inflammation. 
In our cases we observed a granulomatous inflammation of the media layer (chronic 
inflammatory infiltrate with giant cells), with characteristic fragmentation of  the  internal 
limiting lamina and intimal thickening. (fig. 16) 
6. Treatment and evolution 
High-dose corticosteroids are the only effective therapy in GCA. Corticosteroid treatment must 
not be delayed by temporal artery biopsy, because the biopsy is positive even after a few 
days of steroid treatment. The initial dose of prednisone or its equivalent ranges between 40 
and 60 mg/d, as a single or divided dose, for 3–4 weeks . 
In our experience, GCA patients without severe ischemic complications have rapid disease 
improvement with an initial prednisone dose of 40 mg/d. In these patients, the use of 
corticosteroids has dramatically reduced the frequency of severe visual ischemic 
complications. 
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However, in GCA patients who present with visual ischemic manifestations we use higher 
corticosteroid doses—generally an initial intravenous methyl prednisolone pulse therapy (1 
g/d for 3 consecutive days), followed by oral prednisone 60 mg daily for 3–4 weeks.  
To assess whether corticosteroid therapy should be given every other day or as a single or 
divided daily dose, Hunder et al., 1975 carried out a prospective, randomized study to 
compare oral prednisone treatment in a divided dose t.i.d. (15 mg/ 8 h) with a single daily 
dose of prednisone (45 mg) and prednisone every other morning (90 mg) (Hunder et al., 
1975). After 1 month of treatment, they found a trend toward better disease control in the 
divided dose group compared with the single daily dose group, but no differences in the 
side effect profile between the two groups. However, in only 6 of the 20 patients receiving 
prednisone every other morning was the disease completely suppressed. These results 
support the need to start treatment with daily prednisone therapy in patients with GCA. 
A study compared an initial high-dose pulse of IV methylprednisolone versus classic 
corticosteroid therapy. The authors performed a double-blind, placebo controlled, 
randomized, prospective clinical trial: a 3-day course of IV methyl prednisolone pulses (15 
mg/kg of ideal body weight/d) in addition to the oral prednisone (n=14) compared with 
normal IV saline infusions plus oral prednisone (n=13). The initial IV pulse of 
methylprednisolone therapy yielded more rapid corticosteroid tapering, lower median dose 
at each visit, and fewer relapses. However, further studies including larger numbers of 
patients are required to establish the routine use of IV pulse methylprednisolone as the 
initial corticosteroid therapy for the management of GCA (Mazlumzadeh et al., 2006). 
Data show that it is not the absolute dose but rather the time from the onset of symptoms to 
the first administration of corticosteroids that is predictive of improvement of visual loss. 
Regrettably, in most cases, once established, the prognosis for significant visual recovery in 
GCA patients despite corticosteroid therapy is poor. Gonzalez-Gay et al. 2000 assessed the 
outcome of 29 GCA patients who developed loss of vision shortly before their admission to 
the hospital (Gonzalez-Gay et al. 2000). Only 8 patients (28%) experienced visual 
improvement—generally partial—following corticosteroid therapy. The main factor 
influencing the response to corticosteroids was therapeutic delay. Interestingly, 7 of 12 
patients treated within the first 24 h after the onset of visual loss experienced visual 
improvement. However, when corticosteroid therapy was delayed for more than 1 day, only 
1 of the remaining 17 patients experienced some visual recovery. These observations 
indicate that corticosteroid therapy should not be delayed under any circumstances in GCA 
patients with suspected visual impairment.  
In conclusion the aim of the treatment in patients  with GCA with eye involvement is to 
prevent blindness of the fellow eye, although in a few unfortunate patients with initial 
unilateral visual loss, the second eye also became blind inspite of prompt steroid 
administration (Gonzales-Gay et al., 1998). Most GCA symptoms other than blindness 
(headache, etc) usually begin to improve within 24–72 h after the onset of corticosteroid 
therapy. Also, normalization of routine laboratory parameters of inflammation (ESR and 
CRP) occurs within 2–4 weeks after initiation of this therapy. Afterward, the corticosteroid 
dose can be tapered gradually. However, the duration of corticosteroid therapy is variable, 
and relapses often occur. Whenever symptoms or acute phase proteins recur during 
tapering, the last effective dose plus 10 mg should be administered Prednisone is generally 
reduced by 5 mg every 2–4 weeks down to 25 mg. Then it can be reduced by 2.5 mg every 2–
4 weeks until the dose is 10 mg, and later by about 2.5 mg every 2 months. Prednisone 
tapering is then performed more slowly (Gonzales-Gay et al., 2005). 
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The duration of treatment (1-2 years ) is guided by the patient’s symptoms and the levels of 
the ESR and CRP. In some cases from the literature, symptoms may however recur without 
a corresponding increase in ESR or CRP or vice versa, requiring indefinite maintenance 
therapy (Gonzales-Gay et al., 2005). 
Up to 80% of patients with GCA experience complications related to steroid therapy. These 
include diabetes mellitus, osteoporosis with vertebral compression fractures and Cushing 
syndrome. It is advisable to consider the use of bone protection therapy in patients with 
GCA (Gonzales-Gay et al., 2005). 
In this regard, alternative corticosteroid-sparing drugs—in particular methotrexate (MTX)—
should be considered in GCA patients with severe corticosteroid-related side effects and/or 
in patients who require prolonged corticosteroid therapy due to relapses of the disease. 
With respect to this, to reevaluate the efficacy and safety of adjunctive low-dose MTX in 
GCA patients, Mahr et al., 2006 performed an individual patient data meta-analysis of three 
randomized, placebo-controlled trials in patients with newly diagnosed GCA (Mahr et al., 
2006). However, the authors found a modest role of MTX (10–15 mg/ wk) in reducing 
relapse rate and decreasing the cumulative corticosteroid therapy. 
In small trials, anti–tumor necrosis factor–α therapy (infliximab and etanercept) have been 
evaluated in patients with GCA and toxicity secondary to steroid therapy. No clear benefit 
of anti–tumor necrosis factor–α therapy in patients with GCA has been reported. Moreover, 
the limited number of patients on tumor necrosis factor–α blocker agents included in these 
studies does not allow us to draw definitive conclusions about tthese drugs (Gonzales-Gay 
et al., 2005). 
It is known that the presence of traditional atherosclerosis risk factors at the time of 
diagnosis of GCA influences the development of severe ischemic manifestations in patients 
with this type of vasculitis. Interestingly, two retrospective studies suggested that antiplatelet 
and/or anticoagulant therapy may reduce ischemic complications in patients with GCA 
(Nesser et al., 2004). Therefore, antiplatelet therapy started before GCA diagnosis may 
reduce the risk of severe ischemic events in patients with GCA. Thus, aspirin (75–125 mg/d) 
should be prescribed in patients with GCA. However, no positive impact of antiaggregation 
therapy on the risk of severe ischemic complications has been confirmed in more recent 
studies (Lee et al., 2006). 
7. Conclusions 
GCA is a common disease among older adults from Western countries. Higher physician 
awareness may have been responsible for the progressive increase in the incidence of these 
conditions observed in different parts of the world. Diagnostic criteria of GCA are 
represented by age 50 years or more, new develop headache, tenderness of the superficial 
temporal artery, elevated ESR, at least 50 mm/h, and giant cell arteritis in a biopsy specimen 
from the temporal artery. Large vessel giant cell arteritis is a subgroup of GCA  occuring 
also at the level of the aorta and its branches (especially of the subclavian, the axillary 
arteries, etc.). 
The eye involvement in Horton’s disease consists in anterior ischemic optic neuropaty or 
central retinal artery occlusion with abrupt, painless, and severe loss of vision of the 
involved eye.  
The superficial temporal artery biopsy is the gold standard test for the diagnosis of this 
vasculitis. Several imaging modalities, particularly US, are useful in making a diagnosis of 
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GCA (,,dark halo” sign). However, findings of temporal artery US did not correlate with eye 
complications. For this reason, Color Doppler Imaging of the retrobulbar vessels may be 
helpful to detect the blood flow in the orbital vessels, especially in cases of opacity of the 
medium, or when the clinical appearance of ophthalmologic complications in temporal 
arteritis is athypical. The Spectral Doppler Analysis of the orbital vessels in GCA  reveales 
low blood velocities, especially end-diastolic velocities, and high resistance index in all 
retrobulbar vessels, in both orbits, for  all patients (especially on the affected side). 
Corticosteroids are the cornerstone of treatment in GCA. Alternative corticosteroid- sparing 
drugs, in particular MTX, should be considered in GCA patients with severe corticosteroid-
related side effects and/or in patients who require prolonged corticosteroid therapy due to 
relapses of the disease. 
Key words: Giant cell arteritis, temporal headache, superficial temporal artery biopsy, “dark 
halo” sign, central retinal artery obstruction, arteritic anterior ischaemic optic neuropathy. 
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